glp-1 analog drugs Mapping the effectiveness and risks of receptor agonists GLP-1 receptor agonists | How

Description

Our DEXA Body Composition, Bone Density, and Visceral Fat page explains why measuring body composition can be more clinically useful than relying on weight alone

GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S

However, due to the small sample size and restricted scope of the study, it remains unclear whether this phenomenon is induced by the drug itself, which requires further verification

Tirzepatides dual GLP-1R and GIPR agonism may confer distinct anti-inflammatory effects, some of which persist even when neuronal GLP-1R signaling is impaired